| Sorafenib |
NCT02636426 |
Completed |
Phase 1 |
Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study |
Neoplasms |
https://ClinicalTrials.gov/show/NCT02636426 |
| Sorafenib |
NCT02122003 |
Terminated |
Phase 2 |
Second Line Sorafenib After Pazopanib in Patients With RCC |
Metastatic Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02122003 |
| Sorafenib |
NCT02288507 |
Withdrawn |
Phase 1 |
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer |
Hepatocellular Cancer |
https://ClinicalTrials.gov/show/NCT02288507 |
| Sorafenib |
NCT03535259 |
Recruiting |
Phase 2 |
Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma |
Hepatocellular Carcinoma, Radiotherapy, Sorafenib |
https://ClinicalTrials.gov/show/NCT03535259 |
| Sorafenib |
NCT02733809 |
Recruiting |
Phase 4 |
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma |
Hepatocellular Carcinoma |
https://ClinicalTrials.gov/show/NCT02733809 |
| Sorafenib |
NCT01425216 |
Terminated |
Phase 2 |
Sorafenib for Patients With Extensive Keloids |
Keloids |
https://ClinicalTrials.gov/show/NCT01425216 |
| Sorafenib |
NCT02867280 |
Terminated |
Phase 3 |
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection |
Hepatocellular Carcinoma|Recurrence |
https://ClinicalTrials.gov/show/NCT02867280 |
| Sorafenib |
NCT02021929 |
Terminated |
Phase 2 |
Sorafenib for Hepatopulmonary Syndrome |
Hepatopulmonary Syndrome |
https://ClinicalTrials.gov/show/NCT02021929 |
| Sorafenib |
NCT04069949 |
Not yet recruiting |
N/A |
Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus |
Unresectable Hepatocellular Cancer|Portal Vein Tumor Thrombus |
N/A |
| Sorafenib |
NCT02084732 |
Completed |
Phase 2 |
Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study |
Thyroid Cancer |
https://ClinicalTrials.gov/show/NCT02084732 |
| Sorafenib |
NCT03582618 |
Recruiting |
Phase 2 |
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma |
Hepatocellular Carcinoma|Advanced Cancer |
https://ClinicalTrials.gov/show/NCT03582618 |
| Sorafenib |
NCT02560779 |
Completed |
Phase 1|Phase 2 |
Trial of TRC105 and Sorafenib in Patients With HCC |
Hepatocellular Carcinoma |
https://ClinicalTrials.gov/show/NCT02560779 |
| Sorafenib |
NCT03722498 |
Terminated |
Phase 2 |
Phase â…ˇ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE |
Hepatocellular Carcinoma |
https://ClinicalTrials.gov/show/NCT03722498 |
| Sorafenib |
NCT01906216 |
Recruiting |
Phase 2|Phase 3 |
Sorafenib Chemoembolization Evaluation Controlled Trial |
Hepatocellular Carcinoma |
https://ClinicalTrials.gov/show/NCT01906216 |
| Sorafenib |
NCT01471353 |
Completed |
Phase 2 |
Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer |
Colorectal Cancer Metastatic |
https://ClinicalTrials.gov/show/NCT01471353 |
| Sorafenib |
NCT02298348 |
Active, not recruiting |
Phase 1 |
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma |
Neuroblastoma |
https://ClinicalTrials.gov/show/NCT02298348 |
| Sorafenib |
NCT02599337 |
Completed |
Phase 1 |
Bioequivalence Study of Sorafenib Tablet and Nexavar |
Fasting |
https://ClinicalTrials.gov/show/NCT02599337 |
| Sorafenib |
NCT04051853 |
Terminated |
Phase 2 |
Sorafenib PK in Patients With Advanced HCC and Child-Pugh B |
BCLC Stage C HCC|CP-B Liver Cirrhosis |
https://ClinicalTrials.gov/show/NCT04051853 |
| Sorafenib |
NCT01556815 |
Unknown status |
Phase 2 |
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma |
PHENYTOIN/SORAFENIB [VA Drug Interaction]|Liver Neoplasms|Carcinoma, Hepatocellular|Digestive System Neoplasms|Neoplasms by Site|Liver Diseases|Adenocarcinoma|Carcinoma|Neoplasms, Glandular and Epithelial|Neoplasms by Histologic Type|DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]|HBV |
https://ClinicalTrials.gov/show/NCT01556815 |
| Sorafenib |
NCT01203787 |
Completed |
Phase 4 |
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC) |
Hepatocellular Carcinoma |
https://ClinicalTrials.gov/show/NCT01203787 |
| Sorafenib |
NCT02069145 |
Completed |
Phase 1 |
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer |
Hepatocellular Cancer|Liver Cancer |
https://ClinicalTrials.gov/show/NCT02069145 |
| Sorafenib |
NCT02474290 |
Completed |
Phase 2|Phase 3 |
Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML |
Acute Myeloid Leukemia|Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02474290 |
| Sorafenib |
NCT01510756 |
Terminated |
Phase 2 |
Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL) |
Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01510756 |
| Sorafenib |
NCT02311205 |
Unknown status |
Phase 2 |
Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study) |
Hepatocellular Carcinoma|Metastasis |
https://ClinicalTrials.gov/show/NCT02311205 |
| Sorafenib |
NCT01507064 |
Completed |
Phase 2 |
Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma |
Hepatocellular Carcinoma |
https://ClinicalTrials.gov/show/NCT01507064 |
| Sorafenib |
NCT01254890 |
Completed |
Phase 1|Phase 2 |
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome |
Leukemia |
https://ClinicalTrials.gov/show/NCT01254890 |
| Sorafenib |
NCT01561833 |
Completed |
Phase 1 |
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients |
T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01561833 |
| Sorafenib |
NCT02530476 |
Completed |
Phase 1|Phase 2 |
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia |
Leukemia|Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT02530476 |
| Sorafenib |
NCT01444807 |
Unknown status |
Phase 2 |
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases |
Metastatic Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01444807 |
| Sorafenib |
NCT02332031 |
Completed |
Phase 1 |
Sorafenib Drug Drug Interaction Study in Healthy Male Subjects |
Drug Interactions |
https://ClinicalTrials.gov/show/NCT02332031 |
| Sorafenib |
NCT01338857 |
Terminated |
Phase 2 |
Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas |
neurofibromatosis1 (NF1)|Recurrent or Progressive Optic Pathway Gliomas (OPG)|Recurrent or Progressive Low-grade Glioma |
https://ClinicalTrials.gov/show/NCT01338857 |
| Sorafenib |
NCT00780169 |
Completed |
Phase 1 |
Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer |
Metastatic Colorectal Cancer |
https://ClinicalTrials.gov/show/NCT00780169 |
| Sorafenib |
NCT01833299 |
Completed |
Phase 3 |
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma |
Hepatocellular Carcinoma|Face Cancer |
https://ClinicalTrials.gov/show/NCT01833299 |
| Sorafenib |
NCT00997022 |
Completed |
Phase 1 |
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients |
Hepatocellular Cancer |
https://ClinicalTrials.gov/show/NCT00997022 |
| Sorafenib |
NCT01342627 |
Terminated |
Phase 2 |
Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma |
Metastatic Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01342627 |
| Sorafenib |
NCT02691780 |
Withdrawn |
Not Applicable |
Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors |
Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT02691780 |
| Sorafenib |
NCT00875745 |
Completed |
Phase 1 |
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) |
Leukemia, Myeloid, Acute|Leukemia, Promyelocytic, Acute|Myelodysplastic Syndromes |
N/A |
| Sorafenib |
NCT00478114 |
Completed |
Phase 3 |
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC) |
Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT00478114 |
| Sorafenib |
NCT00846131 |
Completed |
Phase 1 |
Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma |
Hepatocellular Carcinoma |
https://ClinicalTrials.gov/show/NCT00846131 |
| Sorafenib |
NCT01398501 |
Completed |
Phase 1 |
Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant |
Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT01398501 |
| Sorafenib |
NCT02834546 |
Recruiting |
N/A |
Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma |
Hepatocellular Carcinoma (HCC) |
https://ClinicalTrials.gov/show/NCT02834546 |
| Sorafenib |
NCT03606590 |
Recruiting |
Phase 2 |
Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) |
Hepatocellular Carcinoma |
https://ClinicalTrials.gov/show/NCT03606590 |
| Sorafenib |
NCT02150317 |
Unknown status |
Not Applicable |
Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma |
Advanced Hepatocellular Carcinoma |
https://ClinicalTrials.gov/show/NCT02150317 |
| Sorafenib |
NCT01334710 |
Terminated |
Phase 2 |
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer |
Liver Cancer |
https://ClinicalTrials.gov/show/NCT01334710 |
| Sorafenib |
NCT01029418 |
Terminated |
Phase 1|Phase 2 |
AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma |
Hepatocellular Carcinoma |
https://ClinicalTrials.gov/show/NCT01029418 |
| Sorafenib |
NCT01328223 |
Unknown status |
N/A |
Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma |
Hepatocellular Carcinoma |
https://ClinicalTrials.gov/show/NCT01328223 |
| Sorafenib |
NCT01736878 |
Withdrawn |
Phase 2 |
Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma |
Medullary Thyroid Carcinoma |
https://ClinicalTrials.gov/show/NCT01736878 |
| Sorafenib |
NCT00933777 |
Completed |
Phase 1 |
SORAVE - Sorafenib and Everolimus in Solid Tumors |
Unspecified Adult Solid Tumor, Protocol Specific|Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT00933777 |
| Sorafenib |
NCT02529761 |
Recruiting |
Not Applicable |
TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma |
Hepatocellular Carcinoma |
https://ClinicalTrials.gov/show/NCT02529761 |
| Sorafenib |
NCT02196857 |
Completed |
Phase 2 |
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation |
Leukemia |
https://ClinicalTrials.gov/show/NCT02196857 |
